José Luis García-Giménez is a Ph.D. Professor Dept. Physiology. Medicine and Dentistry School. University of Valencia. Researcher at the Consortium Center for Biomedical Network Research (CIBER) from Instituto de Salud Carlos III and Principal Investigator of the Research Group of Translational Epigenetics and Epigenomics in the Biomedical Research Institute INCLIVA. He is co-inventor of five patents and co-funder of EpiDisease S.L. (CIBER’s Spin-Off). He received a Bachelor’s in Chemical Science and a Bachelor’s in Biochemistry from the University of Valencia in 2002 and 2004, respectively,
and he earned a Ph.D. in Chemistry in 2007. He was a Post-Doctoral fellow in Hake’s lab at Adolf Butenandt Institute, LMU University, Munich, Germany. He has participated in 37 funded projects (12 as IP and 25 as collaborator) over 17 years. He has over 98 publications in the field of rare diseases, epigenetics, biomarkers, and oxidative stress, and his current research collaborations with clinicians and industry. Dr. García has received nine scientific and entrepreneurship awards, as the National Award for Young Entrepreneurship in 2013 by the Ministry of Health. He received the First Prize in the 2nd China (Jinan) New Growth Drivers International Innovation and Entrepreneurship Contest in 2019 and the First Prize in the 2nd Eurekas International Innovation and Entrepreneurship Competition in Melbourne. In 2022, he received the Real Academia of Medicina de la Comunitat Valenciana award.
Agustin Lahoz holds a Ph.D. in Pharmacy (Organic Chemistry) and an MSc in Biostatistics from the University of Valencia. He is the leader of the Biomarkers and Precision Medicine Unit and the Scientific Director of the Metabolomics Core Facility at the Health Research Institute Hospital La Fe. His laboratory aims to develop and applicate mass spectrometry and stable isotope-assisted metabolomics for studying cellular metabolism and biomarker discovery. Currently, his group focuses on modulating cancer cell metabolism and immune metabolism as avenues for developing more effective therapies.
Federico V Pallardó studied Medicine at the Faculty of Medicine of the University of Valencia where he graduated in 1985 with the qualification of outstanding where he also obtained his doctorate “cum laude”. After passing through the University of Oxford (UK) and Harvard Medical School (USA), where he obtained the prestigious NATO fellowship, he returned to Spain in 1992. He is currently a University Professor and was Dean of the Faculty of Medicine and Dentistry at the University of Valencia between 2011 and 2017. He has been a visiting professor at the Chicago Medical School. He also has been director of the Central Research Unit, coordinating the INCLIVA basic research laboratories for more than ten years. He has been the head of the CIBER group in its rare diseases division since 2007. His research focuses on the role of oxidative stress in the pathophysiology of rare diseases and epigenetic regulation. He is a founding partner of the biotechnological company EPIDISEASE S.L. spin-off of the University of Valencia, CIBERER and INCLIVA. He directs the CIBERER-Biobank of the ISCIII. He has been secretary of the SFRR (Europe) and has received various national and international awards such as the Fundación Salud 2000 Award for his research into rare diseases or the international project Saving Lives at Birth from the Bill and Melinda Gates Foundation. He has been awarded the “SFRR-Europe Annual Award Lecture” by the Society for Free Radical Research in its 2020 edition.
